Overview

A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus. This study aims to assess efficacy and safety in subjects with chronic hepatitis delta virus infection.
Phase:
Phase 2
Details
Lead Sponsor:
Huahui Health